/Biogen%20Inc%20logo%20on%20laptop-by%20monticello%20via%20Shutterstock.jpg)
Biogen Inc. (BIIB), headquartered in Cambridge, Massachusetts, specializes in discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases. Valued at a market capitalization of $20.6 billion, the company's portfolio includes treatments for conditions such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, Crohn's disease, and psoriasis. BIIB is expected to announce its fiscal fourth-quarter earnings for 2024 before the market opens on Tuesday, Feb. 11.
Ahead of the event, analysts expect BIIB to report a profit of $3.43 per share on a diluted basis, up 16.3% from $2.95 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.